A study to evaluate the prognostic value of cetuximab-mediated antibody-dependent cell-mediated cytotoxicity (ADCC) in patients with head and neck squamous cell carcinoma (HNSCC)

Trial Profile

A study to evaluate the prognostic value of cetuximab-mediated antibody-dependent cell-mediated cytotoxicity (ADCC) in patients with head and neck squamous cell carcinoma (HNSCC)

Completed
Phase of Trial: Phase IV

Latest Information Update: 20 Apr 2016

At a glance

  • Drugs Cetuximab (Primary)
  • Indications Head and neck cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Apr 2016 Results presented at the 107th Annual Meeting of the American Association for Cancer Research
    • 18 Apr 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top